{"protocolSection": {"identificationModule": {"nctId": "NCT02500628", "orgStudyIdInfo": {"id": "20150618"}, "organization": {"fullName": "Woodinville Psychiatric Associates", "class": "OTHER"}, "briefTitle": "Heart Rate Variability in Response to Metformin Challenge", "officialTitle": "Heart Rate Variability in Response to Metformin Challenge"}, "statusModule": {"statusVerifiedDate": "2017-12", "overallStatus": "COMPLETED", "expandedAccessInfo": {"hasExpandedAccess": false}, "startDateStruct": {"date": "2015-07"}, "primaryCompletionDateStruct": {"date": "2016-02", "type": "ACTUAL"}, "completionDateStruct": {"date": "2016-02", "type": "ACTUAL"}, "studyFirstSubmitDate": "2015-07-11", "studyFirstSubmitQcDate": "2015-07-14", "studyFirstPostDateStruct": {"date": "2015-07-16", "type": "ESTIMATED"}, "resultsFirstSubmitDate": "2017-05-29", "resultsFirstSubmitQcDate": "2017-12-30", "resultsFirstPostDateStruct": {"date": "2018-01-03", "type": "ACTUAL"}, "lastUpdateSubmitDate": "2017-12-30", "lastUpdatePostDateStruct": {"date": "2018-01-03", "type": "ACTUAL"}}, "sponsorCollaboratorsModule": {"responsibleParty": {"type": "PRINCIPAL_INVESTIGATOR", "investigatorFullName": "Jon Berner MD PhD", "investigatorTitle": "Clinic Director", "investigatorAffiliation": "Woodinville Psychiatric Associates"}, "leadSponsor": {"name": "Woodinville Psychiatric Associates", "class": "OTHER"}}, "oversightModule": {"oversightHasDmc": false}, "descriptionModule": {"briefSummary": "Diseases caused by brain energy supply defects can be innate (fibromyalgia secondary to familial mitochondrial disorders) or acquired (tardive dyskinesia or weight gain associated with prolonged antipsychotic use). Patients with these possible mitochondrial disorders will provide a baseline resting heart rate sample, ingest low-dose metformin (500 mg), and then provide an additional sample 2 hours later.", "detailedDescription": "Doctors need to develop tests which inexpensively and reliably evaluates brain metabolism. Current diagnostic tests sample other tissues which often run on different fuels (fats), utilize unproven and often insensitive brain imaging scanners, or sequence thousands to millions of base-pairs of DNA. All of these tests are expensive. None of these tests accurately or completely capture the interactions between the 1000s of proteins involved in brain metabolism.\n\nThe investigators suspect that mathematical analysis of the resting heart rate may provide some insight into brain metabolism. The brain controls heart rate in response to changes in blood pressure and blood gases like carbon dioxide and oxygen. Tight control of heart rate is necessary to make sure that the brain has the right mix of fuel and air. Because the brain can't respond instantly to changes in its fuel supply, this system acting as a biological carburetor has a natural oscillatory rhythm that can be monitored just like frequencies on the radio.\n\nThe investigators propose to amplify these rhythms by modestly metabolically stressing the brain with metformin, a inhibitor of complex 1 in the mitochondria."}, "conditionsModule": {"conditions": ["Fibromyalgia", "Mitochondrial Diseases", "Movement Disorders", "Diabetes Mellitus, Type 2"], "keywords": ["metformin", "mitochondria", "complex 1", "fibromyalgia", "neurogenic pain", "diabetes", "tardive dyskinesia", "heart rate variability"]}, "designModule": {"studyType": "INTERVENTIONAL", "phases": ["PHASE2"], "designInfo": {"allocation": "NON_RANDOMIZED", "interventionModel": "SINGLE_GROUP", "primaryPurpose": "DIAGNOSTIC", "maskingInfo": {"masking": "NONE"}}, "enrollmentInfo": {"count": 61, "type": "ACTUAL"}}, "armsInterventionsModule": {"armGroups": [{"label": "Fibromyalgia", "type": "EXPERIMENTAL", "description": "Fibromyalgia (subgroups: opioid responsive, opioid resistant, opioid intolerant) Metformin 500 mg orally in the morning", "interventionNames": ["Drug: Metformin"]}, {"label": "Antipsychotic use", "type": "EXPERIMENTAL", "description": "Antipsychotic use (subgroups: no side effects, dyskinesia, weight gain) Metformin 500 mg orally in the morning", "interventionNames": ["Drug: Metformin"]}], "interventions": [{"type": "DRUG", "name": "Metformin", "description": "500 mg orally after baseline testing of heart rate", "armGroupLabels": ["Antipsychotic use", "Fibromyalgia"], "otherNames": ["Glucophage"]}]}, "outcomesModule": {"primaryOutcomes": [{"measure": "Heart Rate Variability (Time Domain)", "description": "ratio of the standard deviation of sampled intervals between each heart beat for ten minutes at time 1 (prior to metformin ingestion) over standard deviation of the sampled intervals between each heart beat for ten minutes at time 2 (2 hours post metformin ingestion)", "timeFrame": "difference pre/post metformin ingestion (2 hours)"}, {"measure": "Heart Rate Variability (Frequency Domain)", "description": "total power in the frequency domain is estimated for 10 minutes prior to metformin ingestion and then divided by the total power in the frequency domain estimated for 10 minutes 2 hours after metformin ingestion. Ratio is log-transformed.", "timeFrame": "difference pre/post metformin ingestion (2 hours)"}], "secondaryOutcomes": [{"measure": "Number of Patients Reporting Side Effects From the Medication", "description": "Patient after testing generated an unprompted list of observed side effects from the medication. Many reported none. Results were scored as the binary presence or absence of side effect", "timeFrame": "2 hours after ingestion"}]}, "eligibilityModule": {"eligibilityCriteria": "Inclusion Criteria:\n\nEITHER chronic neurogenic pain meeting American College of Rheumatology criteria for fibromyalgia or previous/current exposure to antipsychotic medications\n\nExclusion Criteria:\n\n* recent infection,\n* renal failure,\n* pre-existing cardiac disease,\n* chronic obstructive pulmonary disease\n* inability to participate in informed consent,\n* lack of transport to return home from study site,\n* severe fasting intolerance or hypoglycemia,\n* history of stroke-alike episode,\n* uncontrolled migraine or cyclic vomiting,\n* diabetes on insulin or sulfonylurea,\n* non-English speaker,\n* medications with strong effects on baseline heart rate variability", "healthyVolunteers": false, "sex": "ALL", "minimumAge": "18 Years", "stdAges": ["ADULT", "OLDER_ADULT"]}, "contactsLocationsModule": {"overallOfficials": [{"name": "Jon E Berner, MD PhD", "affiliation": "Woodinville Psychiatric Associates", "role": "PRINCIPAL_INVESTIGATOR"}], "locations": [{"facility": "Woodinville Psychiatric Associates", "city": "Woodinville", "state": "Washington", "zip": "98072", "country": "United States", "geoPoint": {"lat": 47.75427, "lon": -122.16346}}]}}, "resultsSection": {"participantFlowModule": {"recruitmentDetails": "7/25/2015 to 2/21/16", "groups": [{"id": "FG000", "title": "Fibromyalgia", "description": "Fibromyalgia (subgroups: opioid responsive, opioid resistant, opioid intolerant) Metformin 500 mg orally in the morning\n\nMetformin: 500 mg orally after baseline testing of heart rate"}, {"id": "FG001", "title": "Antipsychotic Use", "description": "Antipsychotic use (subgroups: no side effects, dyskinesia, weight gain) Metformin 500 mg orally in the morning\n\nMetformin: 500 mg orally after baseline testing of heart rate"}], "periods": [{"title": "Overall Study", "milestones": [{"type": "STARTED", "achievements": [{"groupId": "FG000", "numSubjects": "38"}, {"groupId": "FG001", "numSubjects": "23"}]}, {"type": "COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "38"}, {"groupId": "FG001", "numSubjects": "23"}]}, {"type": "NOT COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "0"}, {"groupId": "FG001", "numSubjects": "0"}]}]}]}, "baselineCharacteristicsModule": {"groups": [{"id": "BG000", "title": "Fibromyalgia", "description": "Fibromyalgia (subgroups: opioid responsive, opioid resistant, opioid intolerant) Metformin 500 mg po in AM\n\nMetformin: 500 mg po after baseline testing of heart rate"}, {"id": "BG001", "title": "Antipsychotic Use", "description": "Antipsychotic use (subgroups: no side effects, dyskinesia, weight gain) Metformin 500 mg po in AM\n\nMetformin: 500 mg po after baseline testing of heart rate"}, {"id": "BG002", "title": "Total", "description": "Total of all reporting groups"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "BG000", "value": "38"}, {"groupId": "BG001", "value": "23"}, {"groupId": "BG002", "value": "61"}]}], "measures": [{"title": "Age, Categorical", "paramType": "COUNT_OF_PARTICIPANTS", "unitOfMeasure": "Participants", "classes": [{"denoms": [{"units": "Participants", "counts": [{"groupId": "BG000", "value": "38"}, {"groupId": "BG001", "value": "23"}, {"groupId": "BG002", "value": "61"}]}], "categories": [{"title": "<=18 years", "measurements": [{"groupId": "BG000", "value": "0"}, {"groupId": "BG001", "value": "0"}, {"groupId": "BG002", "value": "0"}]}, {"title": "Between 18 and 65 years", "measurements": [{"groupId": "BG000", "value": "37"}, {"groupId": "BG001", "value": "23"}, {"groupId": "BG002", "value": "60"}]}, {"title": ">=65 years", "measurements": [{"groupId": "BG000", "value": "1"}, {"groupId": "BG001", "value": "0"}, {"groupId": "BG002", "value": "1"}]}]}]}, {"title": "Age, Continuous", "paramType": "MEAN", "dispersionType": "STANDARD_DEVIATION", "unitOfMeasure": "years", "classes": [{"denoms": [{"units": "Participants", "counts": [{"groupId": "BG000", "value": "38"}, {"groupId": "BG001", "value": "23"}, {"groupId": "BG002", "value": "61"}]}], "categories": [{"measurements": [{"groupId": "BG000", "value": "46.71", "spread": "12.15"}, {"groupId": "BG001", "value": "47.61", "spread": "11.9"}, {"groupId": "BG002", "value": "47.1", "spread": "12.32"}]}]}]}, {"title": "Sex: Female, Male", "paramType": "COUNT_OF_PARTICIPANTS", "unitOfMeasure": "Participants", "classes": [{"denoms": [{"units": "Participants", "counts": [{"groupId": "BG000", "value": "38"}, {"groupId": "BG001", "value": "23"}, {"groupId": "BG002", "value": "61"}]}], "categories": [{"title": "Female", "measurements": [{"groupId": "BG000", "value": "31"}, {"groupId": "BG001", "value": "20"}, {"groupId": "BG002", "value": "51"}]}, {"title": "Male", "measurements": [{"groupId": "BG000", "value": "7"}, {"groupId": "BG001", "value": "3"}, {"groupId": "BG002", "value": "10"}]}]}]}, {"title": "Race and Ethnicity Not Collected", "populationDescription": "Race and Ethnicity were not collected from any participant.", "paramType": "COUNT_OF_PARTICIPANTS", "unitOfMeasure": "Participants", "classes": [{"denoms": [{"units": "Participants", "counts": [{"groupId": "BG000", "value": "0"}, {"groupId": "BG001", "value": "0"}, {"groupId": "BG002", "value": "0"}]}], "categories": [{"measurements": [{"groupId": "BG002", "value": "0"}]}]}]}, {"title": "Region of Enrollment", "paramType": "COUNT_OF_PARTICIPANTS", "unitOfMeasure": "Participants", "classes": [{"title": "United States", "denoms": [{"units": "Participants", "counts": [{"groupId": "BG000", "value": "38"}, {"groupId": "BG001", "value": "23"}, {"groupId": "BG002", "value": "61"}]}], "categories": [{"measurements": [{"groupId": "BG000", "value": "38"}, {"groupId": "BG001", "value": "23"}, {"groupId": "BG002", "value": "61"}]}]}]}]}, "outcomeMeasuresModule": {"outcomeMeasures": [{"type": "PRIMARY", "title": "Heart Rate Variability (Time Domain)", "description": "ratio of the standard deviation of sampled intervals between each heart beat for ten minutes at time 1 (prior to metformin ingestion) over standard deviation of the sampled intervals between each heart beat for ten minutes at time 2 (2 hours post metformin ingestion)", "populationDescription": "Patients with or without fibromyalgia, with or without antipsychotic use.", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "msec/msec", "timeFrame": "difference pre/post metformin ingestion (2 hours)", "groups": [{"id": "OG000", "title": "Fibromyalgia", "description": "Fibromyalgia (subgroups: opioid responsive, opioid resistant, opioid intolerant) Metformin 500 mg po in AM\n\nMetformin: 500 mg po after baseline testing of heart rate"}, {"id": "OG001", "title": "Antipsychotic Use", "description": "Antipsychotic use (subgroups: no side effects, dyskinesia, weight gain) Metformin 500 mg po in AM\n\nMetformin: 500 mg po after baseline testing of heart rate"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "38"}, {"groupId": "OG001", "value": "23"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "0.92", "spread": "0.31"}, {"groupId": "OG001", "value": "0.83", "spread": "0.32"}]}]}], "analyses": [{"groupIds": ["OG000", "OG001"], "groupDescription": "comparison between fibromyalgia and non-fibromyalgia group", "nonInferiorityType": "OTHER", "pValue": "0.77", "statisticalMethod": "t-test, 2 sided"}]}, {"type": "PRIMARY", "title": "Heart Rate Variability (Frequency Domain)", "description": "total power in the frequency domain is estimated for 10 minutes prior to metformin ingestion and then divided by the total power in the frequency domain estimated for 10 minutes 2 hours after metformin ingestion. Ratio is log-transformed.", "populationDescription": "patients with or without fibromyalgia. with or without antipsychotic use", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "ratio", "timeFrame": "difference pre/post metformin ingestion (2 hours)", "groups": [{"id": "OG000", "title": "Fibromyalgia", "description": "Fibromyalgia (subgroups: opioid responsive, opioid resistant, opioid intolerant) Metformin 500 mg orally in the morning\n\nMetformin: 500 mg orally after baseline testing of heart rate"}, {"id": "OG001", "title": "Antipsychotic Use", "description": "Antipsychotic use (subgroups: no side effects, dyskinesia, weight gain) Metformin 500 mg orally in the morning\n\nMetformin: 500 mg orally after baseline testing of heart rate"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "38"}, {"groupId": "OG001", "value": "23"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "-.14", "spread": "0.29"}, {"groupId": "OG001", "value": "-.24", "spread": "0.38"}]}]}], "analyses": [{"groupIds": ["OG000", "OG001"], "nonInferiorityType": "OTHER", "pValue": "0.27", "statisticalMethod": "t-test, 2 sided"}]}, {"type": "SECONDARY", "title": "Number of Patients Reporting Side Effects From the Medication", "description": "Patient after testing generated an unprompted list of observed side effects from the medication. Many reported none. Results were scored as the binary presence or absence of side effect", "reportingStatus": "POSTED", "paramType": "COUNT_OF_PARTICIPANTS", "unitOfMeasure": "Participants", "timeFrame": "2 hours after ingestion", "groups": [{"id": "OG000", "title": "Fibromyalgia", "description": "Fibromyalgia (subgroups: opioid responsive, opioid resistant, opioid intolerant) Metformin 500 mg po in AM\n\nMetformin: 500 mg po after baseline testing of heart rate"}, {"id": "OG001", "title": "Antipsychotic Use", "description": "Antipsychotic use (subgroups: no side effects, dyskinesia, weight gain) Metformin 500 mg po in AM\n\nMetformin: 500 mg po after baseline testing of heart rate"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "38"}, {"groupId": "OG001", "value": "23"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "13"}, {"groupId": "OG001", "value": "9"}]}]}], "analyses": [{"groupIds": ["OG000"], "groupDescription": "difference between fibromyalgia and non-fibromyalgia patients.", "nonInferiorityType": "OTHER", "pValue": "0.92", "statisticalMethod": "t-test, 2 sided"}]}]}, "adverseEventsModule": {"frequencyThreshold": "5", "timeFrame": "2 hours after ingestion of metformin", "description": "Patients provide an unstructured summary of possible side effects. Most reported none. Common side effects of GI distress or somnolence were scored as binary presence or absence", "eventGroups": [{"id": "EG000", "title": "Fibromyalgia", "description": "Fibromyalgia (subgroups: opioid responsive, opioid resistant, opioid intolerant) Metformin 500 mg po in AM\n\nMetformin: 500 mg po after baseline testing of heart rate", "deathsNumAffected": 0, "deathsNumAtRisk": 38, "seriousNumAffected": 0, "seriousNumAtRisk": 38, "otherNumAffected": 13, "otherNumAtRisk": 38}, {"id": "EG001", "title": "Antipsychotic Use", "description": "Antipsychotic use (subgroups: no side effects, dyskinesia, weight gain) Metformin 500 mg po in AM\n\nMetformin: 500 mg po after baseline testing of heart rate", "deathsNumAffected": 0, "deathsNumAtRisk": 23, "seriousNumAffected": 0, "seriousNumAtRisk": 23, "otherNumAffected": 9, "otherNumAtRisk": 23}], "otherEvents": [{"term": "GI distress", "organSystem": "Gastrointestinal disorders", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "notes": "Nausea", "stats": [{"groupId": "EG000", "numEvents": 5, "numAffected": 5, "numAtRisk": 38}, {"groupId": "EG001", "numEvents": 2, "numAffected": 2, "numAtRisk": 23}]}, {"term": "drowsiness", "organSystem": "Nervous system disorders", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 8, "numAffected": 8, "numAtRisk": 38}, {"groupId": "EG001", "numEvents": 7, "numAffected": 7, "numAtRisk": 23}]}]}, "moreInfoModule": {"certainAgreement": {"piSponsorEmployee": true}, "pointOfContact": {"title": "Jon Berner MD PhD", "organization": "Woodinville Psychiatric Associates", "email": "jonbernermd@gmail.com", "phone": "425-481-0429"}}}, "derivedSection": {"miscInfoModule": {"versionHolder": "2024-06-24"}, "conditionBrowseModule": {"meshes": [{"id": "D000005356", "term": "Fibromyalgia"}, {"id": "D000009209", "term": "Myofascial Pain Syndromes"}, {"id": "D000009069", "term": "Movement Disorders"}, {"id": "D000003924", "term": "Diabetes Mellitus, Type 2"}, {"id": "D000028361", "term": "Mitochondrial Diseases"}], "ancestors": [{"id": "D000003920", "term": "Diabetes Mellitus"}, {"id": "D000044882", "term": "Glucose Metabolism Disorders"}, {"id": "D000008659", "term": "Metabolic Diseases"}, {"id": "D000004700", "term": "Endocrine System Diseases"}, {"id": "D000009135", "term": "Muscular Diseases"}, {"id": "D000009140", "term": "Musculoskeletal Diseases"}, {"id": "D000012216", "term": "Rheumatic Diseases"}, {"id": "D000009468", "term": "Neuromuscular Diseases"}, {"id": "D000009422", "term": "Nervous System Diseases"}, {"id": "D000002493", "term": "Central Nervous System Diseases"}], "browseLeaves": [{"id": "M7115", "name": "Diabetes Mellitus", "relevance": "LOW"}, {"id": "M7119", "name": "Diabetes Mellitus, Type 2", "asFound": "Diabetes Mellitus, Type 2", "relevance": "HIGH"}, {"id": "M8486", "name": "Fibromyalgia", "asFound": "Fibromyalgia", "relevance": "HIGH"}, {"id": "M12161", "name": "Myofascial Pain Syndromes", "asFound": "Fibromyalgia", "relevance": "HIGH"}, {"id": "M23341", "name": "Mitochondrial Diseases", "asFound": "Mitochondrial Disease", "relevance": "HIGH"}, {"id": "M12029", "name": "Movement Disorders", "asFound": "Movement Disorders", "relevance": "HIGH"}, {"id": "M13066", "name": "Pain", "relevance": "LOW"}, {"id": "M22574", "name": "Dyskinesias", "relevance": "LOW"}, {"id": "M680", "name": "Tardive Dyskinesia", "relevance": "LOW"}, {"id": "M16355", "name": "Syndrome", "relevance": "LOW"}, {"id": "M11639", "name": "Metabolic Diseases", "relevance": "LOW"}, {"id": "M25403", "name": "Glucose Metabolism Disorders", "relevance": "LOW"}, {"id": "M7862", "name": "Endocrine System Diseases", "relevance": "LOW"}, {"id": "M12092", "name": "Muscular Diseases", "relevance": "LOW"}, {"id": "M12097", "name": "Musculoskeletal Diseases", "relevance": "LOW"}, {"id": "M15045", "name": "Rheumatic Diseases", "relevance": "LOW"}, {"id": "M6323", "name": "Collagen Diseases", "relevance": "LOW"}, {"id": "M12411", "name": "Neuromuscular Diseases", "relevance": "LOW"}, {"id": "M5742", "name": "Central Nervous System Diseases", "relevance": "LOW"}], "browseBranches": [{"abbrev": "BC18", "name": "Nutritional and Metabolic Diseases"}, {"abbrev": "BC19", "name": "Gland and Hormone Related Diseases"}, {"abbrev": "All", "name": "All Conditions"}, {"abbrev": "BC05", "name": "Musculoskeletal Diseases"}, {"abbrev": "BC10", "name": "Nervous System Diseases"}, {"abbrev": "BC23", "name": "Symptoms and General Pathology"}, {"abbrev": "BC17", "name": "Skin and Connective Tissue Diseases"}]}, "interventionBrowseModule": {"meshes": [{"id": "D000008687", "term": "Metformin"}], "ancestors": [{"id": "D000007004", "term": "Hypoglycemic Agents"}, {"id": "D000045505", "term": "Physiological Effects of Drugs"}], "browseLeaves": [{"id": "M11667", "name": "Metformin", "asFound": "Assessment", "relevance": "HIGH"}, {"id": "M16904", "name": "Antipsychotic Agents", "relevance": "LOW"}, {"id": "M4033", "name": "Analgesics, Opioid", "relevance": "LOW"}, {"id": "M10054", "name": "Hypoglycemic Agents", "relevance": "LOW"}], "browseBranches": [{"abbrev": "Hypo", "name": "Hypoglycemic Agents"}, {"abbrev": "All", "name": "All Drugs and Chemicals"}, {"abbrev": "CNSDep", "name": "Central Nervous System Depressants"}, {"abbrev": "PsychDr", "name": "Psychotropic Drugs"}, {"abbrev": "Analg", "name": "Analgesics"}]}}, "hasResults": true}